National Institute of Diabetes and Digestive and Kidney Disorders, Notice of Closed Meeting, 4598 [06-775]

Download as PDF 4598 Federal Register / Vol. 71, No. 18 / Friday, January 27, 2006 / Notices DEPARTMENT OF HEALTH AND HUMAN SERVICES National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Diabetes and Digestive and Kidney Diseases Special Emphasis Panel, Estrogen Receptors and Lactotrophs. Date: February 8, 2006. Time: 5 p.m. to 6 p.m. Agenda: To review and evaluate grant applications. Place: National Institutes of Health, Two Democracy Plaza, 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Barbara A. Woynarowska, PhD, Scientific Review Administrator, Review Branch, DEA, NIDDK, National Institutes of Health, Room 754, 6707 Democracy Boulevard, Bethesda, MD 20892– 5452, (301) 402–7172, woynarowskab@niddk.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 93.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: January 19, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–773 Filed 1–26–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES rmajette on PROD1PC67 with NOTICES National Institutes of Health National Institute of General Medical Sciences; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice VerDate Aug<31>2005 15:17 Jan 26, 2006 Jkt 208001 is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of General Medical Sciences Special Emphasis Panel MARC Post-Baccalaureate Research Education Program (PREP). Date: February 17, 2006. Time: 8 a.m. to 5 p.m. Agenda: To review and evaluate grant applications. Place: Holiday Inn Select Bethesda, 8120 Wisconsin Avenue, Bethesda, MD 20814. Contact Person: Helen R. Sunshine, PhD, Chief, Office of Scientific Review, National Institute of General Medical Sciences, National Institutes of Health, Natcher Building, Room 3AN12F, Bethesda, MD 20892, 301–594–2881, sunshinh@nigms.nih.gov. (Catalogue of Federal Domestic Assistance Program Nos. 93.375, Minority Biomedical Research Support; 93.821, Cell Biology and Biophysics Research; 93.859, Pharmacology, Physiology, and Biological Chemistry Research; 93.862, Genetics and Developmental Biology Research; 93.88, Minority Access to Research Careers; 93.96, Special Minority Initiatives, National Institutes of Health, HHS) Dated: January 19, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy. [FR Doc. 06–774 Filed 1–26–06; 8:45 am] BILLING CODE 1140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES potential new therapeutics for type 1 diabetes. The outcome of the evaluation will be a decision whether NIDDK should support the request and make available contract resources for development of the potential therapeutic to improve the treatment or prevent the development of type 1 diabetes and its complications. The research proposals and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the proposed research projects, the disclosure of which would constitute a clearly unwarranted invasion of personal privacy. Name of Committee: National Institute of Diabetes and Digestive and Kidney Disorders Special Emphasis Panel, Type 1 Diabetes— Rapid Access to Intervention Development. Date: February 1, 2006. Time: 10 a.m.–11 a.m. Agenda: To evaluate requests for preclinical development resources for potential new therapeutics for type 1 diabetes and its complications. Place: 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone Conference Call). Contact Person: Dr. Myrlene Staten, Senior Advisor, Diabetes Translation Research, Division of Diabetes, Endocrinology and Metabolic Diseases, NIDDK, NIH, 6707 Democracy Boulevard, Bethesda, MD 20892– 5460, 301 402–7886. This notice is being published less than 15 days prior to the meeting due to the timing limitations imposed by the review and funding cycle. (Catalogue of Federal Domestic Assistance Program Nos. 93.847, Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive Diseases and Nutrition Research; 98.849, Kidney Diseases, Urology and Hematology Research, National Institutes of Health, HHS) Dated: January 19, 2006. Anna Snouffer, Acting Director, Office of Federal Advisory Committee Policy [FR Doc. 06–775 Filed 1–26–06; 8:45 am] BILLING CODE 4140–1–M National Institutes of Health National Institute of Diabetes and Digestive and Kidney Disorders, Notice of Closed Meeting DEPARTMENT OF HEALTH AND HUMAN SERVICES Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The purpose of this meeting is to evaluate requests for preclinical development resources for National Institutes of Health PO 00000 Frm 00042 Fmt 4703 Sfmt 4703 National Institute of Diabetes and Digestive and Kidney Disorders; Notice of Closed Meeting Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2) notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the E:\FR\FM\27JAN1.SGM 27JAN1

Agencies

[Federal Register Volume 71, Number 18 (Friday, January 27, 2006)]
[Notices]
[Page 4598]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-775]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health


National Institute of Diabetes and Digestive and Kidney 
Disorders, Notice of Closed Meeting

    Pursuant to section 10(d) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. Appendix 2) notice is hereby given of the following 
meeting.
    The meeting will be closed to the public in accordance with the 
provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 
U.S.C., as amended. The purpose of this meeting is to evaluate requests 
for preclinical development resources for potential new therapeutics 
for type 1 diabetes. The outcome of the evaluation will be a decision 
whether NIDDK should support the request and make available contract 
resources for development of the potential therapeutic to improve the 
treatment or prevent the development of type 1 diabetes and its 
complications. The research proposals and the discussions could 
disclose confidential trade secrets or commercial property such as 
patentable material, and personal information concerning individuals 
associated with the proposed research projects, the disclosure of which 
would constitute a clearly unwarranted invasion of personal privacy.

    Name of Committee: National Institute of Diabetes and Digestive 
and Kidney Disorders Special Emphasis Panel, Type 1 Diabetes--Rapid 
Access to Intervention Development.
    Date: February 1, 2006.
    Time: 10 a.m.-11 a.m.
    Agenda: To evaluate requests for preclinical development 
resources for potential new therapeutics for type 1 diabetes and its 
complications.
    Place: 6707 Democracy Boulevard, Bethesda, MD 20892 (Telephone 
Conference Call).
    Contact Person: Dr. Myrlene Staten, Senior Advisor, Diabetes 
Translation Research, Division of Diabetes, Endocrinology and 
Metabolic Diseases, NIDDK, NIH, 6707 Democracy Boulevard, Bethesda, 
MD 20892-5460, 301 402-7886.
    This notice is being published less than 15 days prior to the 
meeting due to the timing limitations imposed by the review and 
funding cycle.

(Catalogue of Federal Domestic Assistance Program Nos. 93.847, 
Diabetes, Endocrinology and Metabolic Research; 93.848, Digestive 
Diseases and Nutrition Research; 98.849, Kidney Diseases, Urology 
and Hematology Research, National Institutes of Health, HHS)

    Dated: January 19, 2006.
Anna Snouffer,
Acting Director, Office of Federal Advisory Committee Policy
[FR Doc. 06-775 Filed 1-26-06; 8:45 am]
BILLING CODE 4140-1-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.